Anatomic Site
You have full text access to this OnlineOpen article
Nasopharyngeal carcinoma in situ : Two cases of an emerging diagnostic entity (pages 1069–1073)Florence Cheung, Siu Wah Pang, Fei Hioe, Kin-Nam Cheung, Anne Lee and Tsz-kok Yau
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1069::AID-CNCR3>3.0.CO;2-3
Two cases of nasopharyngeal carcinoma in situ are presented. Diagnosis was based on epithelial morphology and positive staining by the in situ hybridization Epstein-Barr virus-encoded RNA technique. Radiotherapy was administered in view of the risk of coexisting cancer or cancer progression, and posttherapy biopsies were negative.
You have full text access to this OnlineOpen article
Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis (pages 1074–1080)Thomas C. Böttger, Valentina Youssef, Phillip Dutkowski, Hans Maschek, Walpurga Brenner and Theo Junginger
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1074::AID-CNCR4>3.0.CO;2-8
CD44v4 is a new prognostic parameter for adenocarcinoma of Barrett's esophagus.
You have full text access to this OnlineOpen article
S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma : Implications for adjuvant chemotherapy (pages 1081–1085)Stefano Cascinu, Marco Ligi, Francesco Graziano, Elena Del Ferro, Massimo Valentini, Cesare Grianti, Marcello Bartolucci and Giuseppina Catalano
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1081::AID-CNCR5>3.0.CO;2-B
S-phase fraction (SPF) determined by flow cytometry showed prognostic differences in patients with early stage colorectal carcinoma. Patients with high SPF had a significantly worse recurrence rate and event free survival. These findings may be considered for future investigation regarding adjuvant chemotherapy for colorectal carcinoma patients.
You have full text access to this OnlineOpen article
Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma (pages 1086–1093)Satoshi Murata, Yoshihiro Moriya, Takayuki Akasu, Shin Fujita and Kenichi Sugihara
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1086::AID-CNCR6>3.0.CO;2-6
Surgical intervention resulted in long term survival for some patients who had resectable hepatic and pulmonary metastases from colorectal carcinoma, with acceptable morbidity and no perioperative mortality.
You have full text access to this OnlineOpen article
Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma (pages 1094–1101)Hiroaki Saito, Shunichi Tsujitani, Kuniyuki Katano, Masahide Ikeguchi, Michio Maeta and Nobuaki Kaibara
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1094::AID-CNCR7>3.0.CO;2-8
An elevated serum level of soluble CD44 variant 6 (CD44v6) and expression of CD44v6 are useful indicators of prognosis in patients with diffuse type gastric carcinoma.
You have full text access to this OnlineOpen article
A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma : An Eastern Cooperative Oncology Group study (pages 1102–1108)Gregory P. Kalemkerian, Michael Jiroutek, David S. Ettinger, John A. Dorighi, David H. Johnson and Mack Mabry
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1102::AID-CNCR8>3.0.CO;2-9
The combination of all-trans-retinoic acid and standard chemotherapy in patients with small cell lung carcinoma resulted in excessive toxicity causing premature discontinuation of the retinoic acid in the majority of patients.
You have full text access to this OnlineOpen article
Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors (pages 1109–1117)Albert Kovatich, David M. Friedland, Teresa Druck, Piotr Hadaczek, Kay Huebner, Robert L. Comis, Walter Hauck and Peter A. McCue
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1109::AID-CNCR9>3.0.CO;2-2
3p allelic loss is minimal in typical lung carcinoids but extensive in atypical lung carcinoids; typical carcinoids are strongly positive for Fhit protein, small cell lung carcinomas are negative, and atypical carcinoids express an intermediate level of Fhit.
You have full text access to this OnlineOpen article
A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls (pages 1118–1127)Xifeng Wu, Jun Gu, Christopher I. Amos, Hong Jiang, Waun Ki Hong and Margaret R. Spitz
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1118::AID-CNCR10>3.0.CO;2-8
Benzo[a]pyrene diol epoxide (BPDE) sensitivity may be a biologic marker for the identification of individuals who are susceptible to the carcinogenic effects of tobacco smoke. BPDE and bleomycin sensitivity might represent different repair or sensitivity pathways; however, when these assays are used in parallel, they might refine our ability to identify high risk individuals.
You have full text access to this OnlineOpen article
Desmoplastic and desmoplastic neurotropic melanoma : Experience with 280 patients (pages 1128–1135)Michael J. Quinn, Kerry A. Crotty, John F. Thompson, Alan S. Coates, Christopher J. O'Brien and William H. McCarthy
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1128::AID-CNCR11>3.0.CO;2-7
For 280 patients with desmoplastic and desmoplastic neurotropic melanoma, survival was found to be similar to that for patients with other forms of melanoma. However, regional lymph node metastases were less common, and the local recurrence rate was increased when neurotropism was present.
You have full text access to this OnlineOpen article
Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer (pages 1136–1141)Emilio Bajetta, Laura Biganzoli, Carlo Carnaghi, Maria Di Bartolomeo, Ivo Spagnoli, Antonio Cassata, Emanuele Galante, Luigi Mariani, Corrado Gallo Stampino and Roberto Buzzoni
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1136::AID-CNCR12>3.0.CO;2-6
This Phase II trial evaluated the effectiveness and tolerability of doxifluridine, an oral prodrug of fluorouracil, in 73 elderly patients with advanced breast carcinoma. The treatment was very well tolerated and the overall response rate was 26% (95% confidence interval, 17.4-45.4), with a median duration of 7 months.
You have full text access to this OnlineOpen article
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials (pages 1142–1152)Aman U. Buzdar, Walter Jonat, Anthony Howell, Stephen E. Jones, Carl P. Blomqvist, Charles L. Vogel, Wolfgang Eiermann, Janet M. Wolter, Mark Steinberg, Alan Webster and David Lee
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5
In this survival update based on a combined analysis of two mature Phase III trials in which anastrozole was compared with megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma, it is noted that anastrozole 1 mg resulted in a statistically significant survival advantage (P < 0.025) over megestrol acetate.
You have full text access to this OnlineOpen article
Matrix metalloproteinase-2 immunoreactive protein : A marker of aggressiveness in breast carcinoma (pages 1153–1162)Anne Talvensaari-Mattila, Paavo Pääkkö, Matti Höyhtyä, Guillermo Blanco-Sequeiros and Taina Turpeenniemi-Hujanen
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4
The immunoreactive protein for matrix metalloproteinase-2/gelatinase A in breast carcinoma cells is prognostic of poor survival and is independent of major prognostic variables (lymph node status, tumor size, tumor grade, and hormone receptor status).
You have full text access to this OnlineOpen article
Adenocarcinoma arising in extragonadal endometriosis : An immunohistochemical study (pages 1163–1169)Aaron C. Han, Susan Hovenden, Norman G. Rosenblum and Hernando Salazar
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1163::AID-CNCR15>3.0.CO;2-3
Adenocarcinoma arising in extragonadal endometriosis expresses a unique cytokeratin phenotype that can be helpful in the differential diagnosis when presenting as a colonic tumor. Pathogenesis of this tumor may involve down-regulation of hormone receptor expression and overexpression of p53 oncoprotein.
You have full text access to this OnlineOpen article
A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma (pages 1170–1173)Harry W. Daniell
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1170::AID-CNCR16>3.0.CO;2-2
Men with prominent testicular atrophy at the time of therapeutic orchiectomy have a worse prognosis than those with less atrophy or none.
You have full text access to this OnlineOpen article
Testicular atrophy in therapeutic orchiectomy specimens from men with prostate carcinoma : Association with prior prostate bed radiation and older age (pages 1174–1179)Harry W. Daniell and Edward W. Tam
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1174::AID-CNCR17>3.0.CO;2-2
Testes removed at therapeutic orchiectomy for prostate carcinoma are much more often atrophic in men who have previously received radiation therapy to the prostate bed.
You have full text access to this OnlineOpen article
Cause of death in men diagnosed with prostate carcinoma (pages 1180–1188)William A. Satariano, Kathleen E. Ragland and Stephen K. Van Den Eeden
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1180::AID-CNCR18>3.0.CO;2-1
In nearly 50% of the death certificates of prostate carcinoma patients, a condition other than prostate carcinoma was listed as the underlying cause of death. Cardiovascular disease was associated positively with nonprostate carcinoma death after adjustment for the effects of race, age, and disease stage.
You have full text access to this OnlineOpen article
Vascular pathology of malignant cervical lymphadenopathy : Qualitative and quantitative assessment with power doppler ultrasound (pages 1189–1196)Chih-Hsiu Wu, Mow-Ming Hsu, Yih-Leong Chang and Fon-Jou Hsieh
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1189::AID-CNCR19>3.0.CO;2-1
Increased vascular density and abnormal vascular patterns were demonstrated with precision in malignant cervical lymphadenopathy with power Doppler ultrasound combined with a quantitative image processing system.
You have full text access to this OnlineOpen article
Malignant lymphoma in Thailand : Changes in the frequency of malignant lymphoma determined from a histopathologic and immunophenotypic analysis of 425 cases at Siriraj Hospital (pages 1197–1204)Sanya Sukpanichnant, Dhira Sonakul, Anong Piankijagum, Wanchai Wanachiwanawin, Gavivann Veerakul, Chularatana Mahasandana, Voravarn S. Tanphaichitr and Vinai Suvatte
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1197::AID-CNCR20>3.0.CO;2-#
The incidence of malignant lymphoma cases has been found to be increasing in Thailand, with a high frequency of intermediate to high grade non-Hodgkin's lymphoma of B-cell phenotype reported. This study shows the changing status of the disease in the region.
General Topic
Chemotherapy
You have full text access to this OnlineOpen article
Long term treatment of myeloproliferative disease with interferon-α-2b : Feasibility and efficacy (pages 1205–1213)Harriet S. Gilbert
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8
The safety and efficacy of recombinant interferon-α-2b (rIFN-α-2b) was evaluated in 54 patients with polycythemia vera, essential thrombocythemia, or agnogenic myeloid metaplasia. Treatment with rIFN-α-2b produced regression of splenomegaly, improved peripheral blood counts, and reduced the need for phlebotomy, with some responses sustained for prolonged periods after discontinuation of therapy.
You have full text access to this OnlineOpen article
Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer (pages 1214–1223)Kyriaki Mystakidou, Sofia Befon, Christina Liossi and Lambros Vlachos
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1214::AID-CNCR22>3.0.CO;2-7
In this study, 5-HT3 receptor antagonists, such as tropisetron, were found to be clinically more effective in the control of emesis of far advanced patients than previously used agents.
Chemotherapy: Toxicity
You have full text access to this OnlineOpen article
Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies (pages 1224–1230)Eli Zuckerman, Tsila Zuckerman, Dan Douer, Dajun Qian and Alexandra M. Levine
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6
Severe hepatic dysfunction, including icteric hepatitis and fulminant hepatic failure, is uncommon among patients infected with hepatitis C virus who are treated with intermittent chemotherapy for hematologic malignancies. Interruption of treatment regimens is usually not required.
Immunotherapy
You have full text access to this OnlineOpen article
Idiopathic giant cell myocarditis after autologous hematopoietic stem cell transplantation and interleukin-2 immunotherapy : A case report (pages 1231–1236)Cristina I. Truica, Christian H. Hansen, David F. Garvin and Kenneth R. Meehan
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1231::AID-CNCR24>3.0.CO;2-5
Giant cell myocarditis may occur with interleukin-2 immunotherapy. The myocardial damage may be due to the activation of lymphocytes against myocardial cells.
Liver
You have full text access to this OnlineOpen article
Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors (pages 1237–1243)Dympna M. Kelly, Sukru Emre, Stephen R. Guy, Charles M. Miller, Myron E. Schwartz and Patricia A. Sheiner
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1237::AID-CNCR25>3.0.CO;2-5
While receiving cyclosporine- or tacrolimus-based immunosuppressive regimens, liver transplant recipients are not at increased risk for developing nonlymphoid solid organ tumors or for dying from such tumors. In addition, a history of previously treated malignancy is not an absolute contraindication to liver transplantation.
Pain Associated with Cancer
You have full text access to this OnlineOpen article
Age, pain intensity, and opioid dose in patients with advanced cancer (pages 1244–1250)Antonio Viganó, Eduardo Bruera and Maria E. Suarez-Almazor
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1244::AID-CNCR26>3.0.CO;2-4
Elderly patients with advanced cancer experience a similar level of pain intensity but require a lower amount of opioid analgesia than younger adults. However, they are more likely to be affected by the acute and chronic toxicities of opioids. Therefore, opioids should be initially administered at a lower dose and titrated cautiously in these patients.
Peritoneal Carcinomatosis
You have full text access to this OnlineOpen article
A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis (pages 1251–1261)David L. Bartlett, Joseph F. Buell, Steven K. Libutti, Eddie Reed, Kang Bo Lee, William D. Figg, David J. Venzon and H. Richard Alexander
Article first published online: 9 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1251::AID-CNCR27>3.0.CO;2-3
The combination of tumor debulking and intraoperative intraperitoneal therapy with hyperthermia, tumor necrosis factor, and cisplatin was shown to be feasible in this Phase I trial of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis. The maximum tolerated dose of cisplatin and tumor necrosis factor are defined.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cover image for Cancer")